• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

    4/14/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email

    - Company to host conference call and webcast on May 8, 2025, at 8:00 a.m. ET (8:00 p.m. HKT)

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on May 8, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).

    Conference Call and Webcast Information

    Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

    Details are as follows:

    Registration link for webcast: https://edge.media-server.com/mmc/p/pwq4a9of

    Registration link for dial-in: https://register-conf.media-server.com/register/BIb40d2ed331c84e39982d7fe2b6ed496f

    All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering. A replay will be available shortly after the call and can be accessed by visiting the Company's website.

    About Zai Lab

    Zai Lab (NASDAQ:ZLAB, HKEX: 9688)) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

    For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250414204385/en/

    For more information, please contact:

    Investor Relations:

    Christine Chiou / Lina Zhang

    +1 (917) 886-6929 / +86 136 8257 6943

    [email protected] / [email protected]

    Media:

    Shaun Maccoun / Xiaoyu Chen

    +1 (857) 270-8854 / +86 185 0015 5011

    [email protected] / [email protected]

    Get the next $ZLAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Zai Lab with a new price target

      Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:00:31 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab downgraded by BofA Securities with a new price target

      BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

      3/3/25 7:38:45 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Zai Lab with a new price target

      Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

      12/14/23 7:54:36 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

        Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

      6/11/24 4:05:00 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Appoints Michel Vounatsos To Its Board of Directors

      SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

      1/9/23 7:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

      SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

      1/3/23 8:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care